688317 之江生物
已收盘 08-28 15:00:01
资讯
新帖
简况
之江生物(688317.SH)发布半年度业绩，归母净亏损4059万元
智通财经 · 08-27 18:54
之江生物(688317.SH)发布半年度业绩，归母净亏损4059万元
图解之江生物中报：第二季度单季净利润同比下降344.54%
证券之星 · 08-27 18:47
图解之江生物中报：第二季度单季净利润同比下降344.54%
每周股票复盘：之江生物（688317）获猴痘病毒检测注册证
证券之星 · 08-23
每周股票复盘：之江生物（688317）获猴痘病毒检测注册证
股市必读：之江生物新发布《之江生物：关于自愿披露公司产品获得相关认证的公告》
证券之星 · 08-21
股市必读：之江生物新发布《之江生物：关于自愿披露公司产品获得相关认证的公告》
之江生物（688317）披露公司产品获得国家三类医疗器械注册证，8月19日股价下跌6.0%
证券之星 · 08-19
之江生物（688317）披露公司产品获得国家三类医疗器械注册证，8月19日股价下跌6.0%
之江生物：猴痘病毒核酸检测试剂盒获国家三类医疗器械注册证
格隆汇 · 08-19
之江生物：猴痘病毒核酸检测试剂盒获国家三类医疗器械注册证
股市必读：之江生物新发布《之江生物：2026年第一次临时股东会决议公告》
证券之星 · 08-17
股市必读：之江生物新发布《之江生物：2026年第一次临时股东会决议公告》
每周股票复盘：之江生物（688317）部分募投项目结项并再投入
证券之星 · 08-16
每周股票复盘：之江生物（688317）部分募投项目结项并再投入
之江生物（688317）披露关于部分募投项目结项并将节余募集资金投入新项目及其他募投项目暨向全资孙公司增资的议案，8月14日股价下跌0.34%
证券之星 · 08-14
之江生物（688317）披露关于部分募投项目结项并将节余募集资金投入新项目及其他募投项目暨向全资孙公司增资的议案，8月14日股价下跌0.34%
股市必读：之江生物新发布《之江生物：2026年第一次临时股东会会议资料》
证券之星 · 08-10
股市必读：之江生物新发布《之江生物：2026年第一次临时股东会会议资料》
每周股票复盘：之江生物（688317）回购股份超8591万元
证券之星 · 08-09
每周股票复盘：之江生物（688317）回购股份超8591万元
之江生物（688317）披露募投项目结项及募集资金用途变更公告，8月6日股价下跌0.42%
证券之星 · 08-06
之江生物（688317）披露募投项目结项及募集资金用途变更公告，8月6日股价下跌0.42%
股市必读：之江生物新发布《之江生物：关于2025年第三次以集中竞价交易方式回购公司股份的进展公告》
证券之星 · 08-06
股市必读：之江生物新发布《之江生物：关于2025年第三次以集中竞价交易方式回购公司股份的进展公告》
股市必读：之江生物新发布《之江生物：关于2025年第三次以集中竞价交易方式回购公司股份的进展公告》
证券之星 · 08-05
股市必读：之江生物新发布《之江生物：关于2025年第三次以集中竞价交易方式回购公司股份的进展公告》
之江生物（688317）披露关于部分募投项目结项并将节余募集资金投入新项目暨向全资孙公司增资的议案，7月29日股价上涨1.86%
证券之星 · 07-29
之江生物（688317）披露关于部分募投项目结项并将节余募集资金投入新项目暨向全资孙公司增资的议案，7月29日股价上涨1.86%
股市必读：之江生物（688317）7月23日董秘有最新回复
证券之星 · 07-24
股市必读：之江生物（688317）7月23日董秘有最新回复
之江生物：公司的用工策略根据业务发展及项目落地情况动态匹配
证券之星 · 07-23
之江生物：公司的用工策略根据业务发展及项目落地情况动态匹配
之江生物：已与上海全球健康创新研究院签署战略合作协议
证券之星 · 07-22
之江生物：已与上海全球健康创新研究院签署战略合作协议
之江生物：已建立多个肿瘤模型并实现科研服务落地
证券之星 · 07-20
之江生物：已建立多个肿瘤模型并实现科研服务落地
股市必读：之江生物（688317）7月15日董秘有最新回复
证券之星 · 07-16
股市必读：之江生物（688317）7月15日董秘有最新回复
加载更多
公司概况
公司名称：
上海之江生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2021-01-18
主营业务：
上海之江生物科技股份有限公司的主营业务是专注于分子诊断试剂和仪器设备的研发、生产和销售。公司的主要产品是分子诊断试剂、仪器设备。
发行价格：
43.22
{"stockData":{"symbol":"688317","market":"SH","secType":"STK","nameCN":"之江生物","latestPrice":17.2,"timestamp":1787900401000,"preClose":17.31,"halted":0,"volume":1951280,"delay":0,"changeRate":-0.0064,"floatShares":190000000,"shares":190000000,"eps":-0.3426,"marketStatus":"已收盘","change":-0.11,"latestTime":"08-28 15:00:01","open":17.19,"high":17.62,"low":17.02,"amount":33780400,"amplitude":0.0347,"askPrice":17.2,"askSize":22,"bidPrice":17.19,"bidSize":46,"shortable":0,"etf":0,"ttmEps":-0.3426,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788139800000},"marketStatusCode":5,"adr":0,"adjPreClose":17.31,"symbolType":"stock_kcb","openAndCloseTimeList":[[1787880600000,1787887800000],[1787893200000,1787900400000]],"highLimit":19.04,"lowLimit":15.58,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":189843712,"isCdr":false,"pbRate":1,"roa":"--","roe":"--","epsLYR":-0.19,"committee":0.152074,"marketValue":3265000000,"turnoverRate":0.0103,"status":1,"afterMarket":{"amount":0,"volume":0,"close":17.2,"buyVolume":0,"sellVolume":0,"time":1787902437746,"indexStatus":"已收盘 08-28 15:30:00","preClose":17.31},"floatMarketCap":3265000000},"requestUrl":"/m/hq/s/688317","defaultTab":"news","newsList":[{"id":"2662022706","title":"之江生物(688317.SH)发布半年度业绩，归母净亏损4059万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662022706","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662022706?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:54","pubTimestamp":1787828088,"startTime":"0","endTime":"0","summary":"智通财经APP讯，之江生物(688317.SH)披露2026年半年度报告，报告期公司实现营业收入5339万元，同比下降10.55%;归属于上市公司股东的净利润亏损4059万元，同比扩大;归属于上市公司股东的扣除非经常性损益的净利润亏损4521万元，同比扩大;基本每股收益-0.23元。报告期公司利润总额、归属于上市公司股东的净利润和归属于上市公司股东的扣除非经常性损益的净利润为负且亏损较去年同期增加，主要系报告期内公司汇兑损失增加、销售收入下降等原因所致。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487172.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"之江生物(688317.SH)发布半年度业绩，归母净亏损4059万元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662970647","title":"图解之江生物中报：第二季度单季净利润同比下降344.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662970647","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662970647?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:47","pubTimestamp":1787827622,"startTime":"0","endTime":"0","summary":"证券之星消息，之江生物2026年中报显示，上半年度公司主营收入5338.82万元，同比下降10.55%；归母净利润-4058.94万元，同比下降312.03%；扣非净利润-4520.73万元，同比下降241.26%；其中2026年第二季度，公司单季度主营收入2796.9万元，同比上升1.53%；单季度归母净利润-1507.92万元，同比下降344.54%；单季度扣非净利润-1806.22万元，同比下降609.24%；负债率10.82%，投资收益244.5万元，财务费用399.55万元，毛利率65.05%。财报数据概要请见下图:本文数据来源于之江生物2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700044955.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661592214","title":"每周股票复盘：之江生物（688317）获猴痘病毒检测注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2661592214","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661592214?lang=zh_cn&edition=full","pubTime":"2026-08-23 03:41","pubTimestamp":1787427670,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，之江生物报收于17.7元，较上周的17.65元上涨0.28%。本周，之江生物8月17日盘中最高价报19.21元。之江生物当前最新总市值33.6亿元，在医疗器械板块市值排名95/129，在两市A股市值排名4058/5210。该试剂盒用于体外定性检测猴痘疑似病例及其他需进行猴痘病毒感染诊断或鉴别诊断者皮肤病变样本中猴痘病毒核酸。产品获得认证后将丰富公司产品种类，完善分子诊断产品矩阵，提升市场竞争力。同时提示存在市场竞争及利润贡献不确定性风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661231579","title":"股市必读：之江生物新发布《之江生物：关于自愿披露公司产品获得相关认证的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2661231579","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661231579?lang=zh_cn&edition=full","pubTime":"2026-08-21 02:27","pubTimestamp":1787250430,"startTime":"0","endTime":"0","summary":"公司公告汇总之江生物：关于自愿披露公司产品获得相关认证的公告上海之江生物科技股份有限公司1项产品近期获得国家三类医疗器械注册证，产品名称为猴痘病毒核酸检测试剂盒，注册证有效期为2026年8月17日至2031年8月16日，注册分类为III类，适用于猴痘病毒核酸检测。该试剂盒用于体外定性检测猴痘疑似病例及其他需进行猴痘病毒感染诊断或鉴别诊断者皮肤病变样本中猴痘病毒核酸。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100001905.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660445429","title":"之江生物（688317）披露公司产品获得国家三类医疗器械注册证，8月19日股价下跌6.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660445429","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660445429?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:28","pubTimestamp":1787149695,"startTime":"0","endTime":"0","summary":"截至2026年8月19日收盘，之江生物报收于17.39元，较前一交易日下跌6.0%，最新总市值为33.01亿元。该股当日开盘18.11元，最高18.46元，最低17.32元，成交额达6416.01万元，换手率为1.91%。近日，之江生物发布《关于自愿披露公司产品获得相关认证的公告》称，公司1项产品近期获得国家三类医疗器械注册证，产品名称为猴痘病毒核酸检测试剂盒，注册证有效期为2026年8月17日至2031年8月16日，注册分类为III类，适用于猴痘病毒核酸检测。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900043360.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK1574","BK1100","09996","BK1583","159883","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660449807","title":"之江生物：猴痘病毒核酸检测试剂盒获国家三类医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2660449807","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660449807?lang=zh_cn&edition=full","pubTime":"2026-08-19 17:11","pubTimestamp":1787130699,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["159883","688317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660710889","title":"股市必读：之江生物新发布《之江生物：2026年第一次临时股东会决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660710889","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660710889?lang=zh_cn&edition=full","pubTime":"2026-08-17 03:15","pubTimestamp":1786907714,"startTime":"0","endTime":"0","summary":"公司公告汇总之江生物：2026年第一次临时股东会决议公告上海之江生物科技股份有限公司于2026年8月14日召开2026年第一次临时股东会，审议通过《关于部分募投项目结项并将节余募集资金投入新项目及其他募投项目暨向全资孙公司增资的议案》。浙江天册律师事务所关于上海之江生物科技股份有限公司2026年第一次临时股东会的法律意见书浙江天册律师事务所就上海之江生物科技股份有限公司2026年第一次临时股东会出具法律意见书。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700001206.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659176957","title":"每周股票复盘：之江生物（688317）部分募投项目结项并再投入","url":"https://stock-news.laohu8.com/highlight/detail?id=2659176957","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659176957?lang=zh_cn&edition=full","pubTime":"2026-08-16 03:13","pubTimestamp":1786821189,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，之江生物报收于17.65元，较上周的17.11元上涨3.16%。本周，之江生物8月12日盘中最高价报18.08元。之江生物当前最新总市值33.51亿元，在医疗器械板块市值排名98/129，在两市A股市值排名4078/5207。浙江天册律师事务所就本次股东会出具法律意见书，确认会议召集、召开程序及表决结果合法有效。出席会议的股东及代理人共10人，持股占比37.75%；网络投票股东139人，持股占比1.04%。议案同意票占有效表决权的99.04%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000936.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659147050","title":"之江生物（688317）披露关于部分募投项目结项并将节余募集资金投入新项目及其他募投项目暨向全资孙公司增资的议案，8月14日股价下跌0.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659147050","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659147050?lang=zh_cn&edition=full","pubTime":"2026-08-14 22:36","pubTimestamp":1786718178,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，之江生物报收于17.65元，较前一交易日下跌0.34%，最新总市值为33.51亿元。该股当日开盘17.61元，最高17.93元，最低17.35元，成交额达3473.64万元，换手率为1.04%。之江生物于近日披露《2026年第一次临时股东会决议公告》。公告显示，公司于2026年8月14日召开2026年第一次临时股东会，审议通过《关于部分募投项目结项并将节余募集资金投入新项目及其他募投项目暨向全资孙公司增资的议案》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400040735.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658608643","title":"股市必读：之江生物新发布《之江生物：2026年第一次临时股东会会议资料》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658608643","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658608643?lang=zh_cn&edition=full","pubTime":"2026-08-10 02:46","pubTimestamp":1786301172,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，之江生物报收于17.11元，上涨2.82%，换手率1.9%，成交量3.61万手，成交额6074.31万元。公司公告汇总之江生物：2026年第一次临时股东会会议资料上海之江生物科技股份有限公司拟对“分子诊断工程研发中心建设项目”和“营销与服务网络升级项目”进行结项，节余募集资金合计20,622.72万元。其中14,473.66万元用于新项目“诊疗技术研发项目”，6,149.06万元投入在建募投项目“产品研发项目”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000001196.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658675166","title":"每周股票复盘：之江生物（688317）回购股份超8591万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658675166","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658675166?lang=zh_cn&edition=full","pubTime":"2026-08-09 03:02","pubTimestamp":1786215736,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，之江生物报收于17.11元，较上周的16.13元上涨6.08%。本周，之江生物8月7日盘中最高价报17.18元。之江生物当前最新总市值32.48亿元，在医疗器械板块市值排名97/129，在两市A股市值排名4112/5205。本周关注点公司公告汇总：之江生物累计回购股份4,372,495股，已支付资金总额85,919,562.37元。2026年7月单月回购144,000股，支付资金2,220,869.78元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657658384","title":"之江生物（688317）披露募投项目结项及募集资金用途变更公告，8月6日股价下跌0.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657658384","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657658384?lang=zh_cn&edition=full","pubTime":"2026-08-06 22:38","pubTimestamp":1786027095,"startTime":"0","endTime":"0","summary":"截至2026年8月6日收盘，之江生物报收于16.64元，较前一交易日下跌0.42%，最新总市值为31.59亿元。该股当日开盘16.65元，最高16.76元，最低16.49元，成交额达2176.95万元，换手率为0.69%。近日，之江生物披露《2026年第一次临时股东会会议资料》。公司拟通过全资子公司向全资孙公司之江细胞技术（上海）有限公司和上海之江再生医学技术有限公司分别增资3,000万元，合计增资6,000万元以实施新项目。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600040102.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657524134","title":"股市必读：之江生物新发布《之江生物：关于2025年第三次以集中竞价交易方式回购公司股份的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657524134","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657524134?lang=zh_cn&edition=full","pubTime":"2026-08-06 02:21","pubTimestamp":1785954071,"startTime":"0","endTime":"0","summary":"公司公告汇总：截至2026年7月31日，之江生物累计回购股份4,372,495股，占总股本2.30%，已支付回购资金85,919,562.37元。公司公告汇总之江生物：关于2025年第三次以集中竞价交易方式回购公司股份的进展公告上海之江生物科技股份有限公司于2025年10月15日召开董事会，审议通过以集中竞价交易方式回购股份的方案，回购期限为2025年10月15日至2026年10月14日，拟回购金额为6,000万元至12,000万元，回购价格不超过37.99元/股，用途为员工持股计划或股权激励。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600001917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657630335","title":"股市必读：之江生物新发布《之江生物：关于2025年第三次以集中竞价交易方式回购公司股份的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657630335","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657630335?lang=zh_cn&edition=full","pubTime":"2026-08-05 02:20","pubTimestamp":1785867618,"startTime":"0","endTime":"0","summary":"公司公告汇总：截至2026年7月31日，之江生物累计回购股份4,372,495股，占总股本2.30%，已支付资金总额8591.96万元。公司公告汇总之江生物：关于2025年第三次以集中竞价交易方式回购公司股份的进展公告上海之江生物科技股份有限公司于2025年10月15日召开董事会，审议通过以集中竞价交易方式回购股份的方案，回购期限为2025年10月15日至2026年10月14日，拟回购金额为6,000万元至12,000万元，回购价格不超过37.99元/股，用途为员工持股计划或股权激励。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500002045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655891838","title":"之江生物（688317）披露关于部分募投项目结项并将节余募集资金投入新项目暨向全资孙公司增资的议案，7月29日股价上涨1.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655891838","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655891838?lang=zh_cn&edition=full","pubTime":"2026-07-29 22:42","pubTimestamp":1785336139,"startTime":"0","endTime":"0","summary":"截至2026年7月29日收盘，之江生物报收于15.84元，较前一交易日上涨1.86%，最新总市值为30.07亿元。近日，之江生物发布《关于召开2026年第一次临时股东会的通知》，公告显示公司将于2026年8月14日召开2026年第一次临时股东会，会议采取现场与网络投票相结合方式，网络投票通过上海证券交易所系统进行。会议审议《关于部分募投项目结项并将节余募集资金投入新项目及其他募投项目暨向全资孙公司增资的议案》，对中小投资者单独计票。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900040782.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653636720","title":"股市必读：之江生物（688317）7月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2653636720","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653636720?lang=zh_cn&edition=full","pubTime":"2026-07-24 02:26","pubTimestamp":1784831173,"startTime":"0","endTime":"0","summary":"截至2026年7月23日收盘，之江生物报收于15.9元，上涨5.65%，换手率1.74%，成交量3.3万手，成交额5113.89万元。董秘最新回复投资者： 员工成长与团队稳定直接关系企业长远价值，梳理贵司2024-2025年报，员工总数同比下降3.51%，人均营业收入同步下滑27.59%，想弄清指标双双回落的根本成因？想了解未来一年公司是否继续压缩用工规模。当日关注点交易信息汇总：7月23日主力资金净流入96.11万元，游资资金净流入324.89万元，散户资金净流出420.99万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400001658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653974936","title":"之江生物：公司的用工策略根据业务发展及项目落地情况动态匹配","url":"https://stock-news.laohu8.com/highlight/detail?id=2653974936","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653974936?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:27","pubTimestamp":1784802426,"startTime":"0","endTime":"0","summary":"证券之星消息，之江生物07月23日在投资者关系平台上答复投资者关心的问题。想了解未来一年公司是否继续压缩用工规模。建议2026年年报细化员工培训、核心人才留存数据，同步告知企业落地哪些举措优化人均经营效益、留住在岗员工。公司的用工策略根据业务发展及项目落地情况动态匹配。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300038051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653572759","title":"之江生物：已与上海全球健康创新研究院签署战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2653572759","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653572759?lang=zh_cn&edition=full","pubTime":"2026-07-22 18:03","pubTimestamp":1784714595,"startTime":"0","endTime":"0","summary":"证券之星消息，之江生物07月22日在投资者关系平台上答复投资者关心的问题。公司始终密切关注国家及上海市相关产业政策与发展方向。公司已与上海全球健康创新研究院签署战略合作协议，共同推动传染病诊断产品出海能力建设。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200037444.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652529293","title":"之江生物：已建立多个肿瘤模型并实现科研服务落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2652529293","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652529293?lang=zh_cn&edition=full","pubTime":"2026-07-20 15:33","pubTimestamp":1784532791,"startTime":"0","endTime":"0","summary":"证券之星消息，之江生物(688317)07月20日在投资者关系平台上答复投资者关心的问题。投资者提问：公司能不能汇报下，类器官投入和研究相关进展情况？之江生物回复：尊敬的投资者，您好！公司已建立多个肿瘤模型并实现科研服务落地，后续将向GMP体系及行业标准升级。同时，公司依托该类器官高通量筛选评价平台，聚焦肿瘤、自身免疫及感染性疾病，已实现从早期发现到候选分子的高效转化。未来，公司将持续关注行业动态，发挥研发优势，积极把握市场机遇，推动技术创新与业务发展。感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000018232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651493148","title":"股市必读：之江生物（688317）7月15日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2651493148","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651493148?lang=zh_cn&edition=full","pubTime":"2026-07-16 03:24","pubTimestamp":1784143451,"startTime":"0","endTime":"0","summary":"截至2026年7月15日收盘，之江生物报收于16.18元，上涨3.06%，换手率1.72%，成交量3.27万手，成交额5304.3万元。董秘最新回复投资者： 请问公司目前埃博拉试剂产能是多少？公司现有产能能够充分满足当前市场需求，产能利用率处于合理水平。具体经营情况请以公司正式披露的定期报告或公告为准。当日关注点交易信息汇总：7月15日主力资金净流出143.27万元，游资资金净流入161.27万元，散户资金净流出18.01万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600004078.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787905536690,"stockEarnings":[{"period":"1week","weight":-0.0463},{"period":"1month","weight":0.1132},{"period":"3month","weight":-0.2203},{"period":"6month","weight":-0.1785},{"period":"1year","weight":-0.3267},{"period":"ytd","weight":-0.1418}],"compareEarnings":[{"period":"1week","weight":0.0135},{"period":"1month","weight":0.0376},{"period":"3month","weight":-0.0275},{"period":"6month","weight":-0.0496},{"period":"1year","weight":0.0411},{"period":"ytd","weight":-0.0031}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海之江生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"13988人(较上一季度减少9.75%)","perCapita":"13571股","listingDate":"2021-01-18","address":"上海市浦东新区张江高科技产业东区瑞庆路528号20幢乙号1层、21幢甲号1层","registeredCapital":"18984万元","survey":" 上海之江生物科技股份有限公司的主营业务是专注于分子诊断试剂和仪器设备的研发、生产和销售。公司的主要产品是分子诊断试剂、仪器设备。","listedPrice":43.22},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"之江生物(688317)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供之江生物(688317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"之江生物,688317,之江生物股票,之江生物股票老虎,之江生物股票老虎国际,之江生物行情,之江生物股票行情,之江生物股价,之江生物股市,之江生物股票价格,之江生物股票交易,之江生物股票购买,之江生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"之江生物(688317)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供之江生物(688317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}